Madison Asset Management LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 79,651 shares of the company's stock, valued at approximately $20,043,000.
A number of other hedge funds also recently bought and sold shares of the business. Csenge Advisory Group bought a new position in AbbVie during the 2nd quarter valued at approximately $6,331,000. AssuredPartners Investment Advisors LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $6,372,000. Shepherd Financial Partners LLC bought a new position in shares of AbbVie during the second quarter valued at approximately $6,430,000. Johnson Financial Group Inc. bought a new position in shares of AbbVie during the second quarter valued at approximately $8,538,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in AbbVie in the second quarter worth $84,575,000. Hedge funds and other institutional investors own 70.23% of the company's stock.
Analyst Ratings Changes
ABBV has been the topic of several recent analyst reports. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. lifted their price objective on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Finally, HSBC reiterated a "buy" rating and set a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $275.95.
Read Our Latest Research Report on ABBV
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
- Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
- Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
- Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?
Insider Buying and Selling
In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company's stock.
AbbVie Price Performance
NYSE:ABBV opened at $256.08 on Monday. The firm's 50-day moving average price is $252.66 and its 200-day moving average price is $228.91. The company has a market capitalization of $452.44 billion, a PE ratio of 72.34, a P/E/G ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.
AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is 195.48%.
About AbbVie
(
Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
